AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Karyopharm Therapeutics Inc.
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001V0G6X5
0.52▼ 0.03 (-5.24%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
—
Trailing P/E
—
Price / Sales
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
—
Trading Information
Previous Close
0.55
Day's Range
0.44 – 0.56
52-Week Range
0.31 – 10.99
Volume
2.0M
Avg Volume
1.6M
Share Statistics
Shares Outstanding
Employees
228
Exchange
XNAS
Listed
2013-11-06
Share count as of August 6, 2026

Karyopharm Therapeutics Inc. (KPTI) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Karyopharm Therapeutics Inc. (KPTI)
What is Karyopharm Therapeutics Inc.'s Market Cap?
Karyopharm Therapeutics Inc.'s Market Cap is $11.7M, based on as-reported figures from SEC (XBRL) filings.
What is Karyopharm Therapeutics Inc.'s Price / Sales?
Karyopharm Therapeutics Inc.'s Price / Sales is 0.1×, based on as-reported figures from SEC (XBRL) filings.
What is Karyopharm Therapeutics Inc.'s Revenue (TTM)?
Karyopharm Therapeutics Inc.'s Revenue (TTM) is $146.6M, based on as-reported figures from SEC (XBRL) filings.
What is Karyopharm Therapeutics Inc.'s Net Income (TTM)?
Karyopharm Therapeutics Inc.'s Net Income (TTM) is -$224.7M, based on as-reported figures from SEC (XBRL) filings.
What is Karyopharm Therapeutics Inc.'s EBITDA?
Karyopharm Therapeutics Inc.'s EBITDA is -$82.2M, based on as-reported figures from SEC (XBRL) filings.
What is Karyopharm Therapeutics Inc.'s Diluted EPS (TTM)?
Karyopharm Therapeutics Inc.'s Diluted EPS (TTM) is -9.91, based on as-reported figures from SEC (XBRL) filings.
What is Karyopharm Therapeutics Inc.'s EBITDA Margin?
Karyopharm Therapeutics Inc.'s EBITDA Margin is -56.1%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · KPTIAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenues:
Revenue from contract with customer, license and other revenue
YoY growth-11.9%+16.8%+11.6%+13.6%
Operating expenses:
Cost of sales
Research and development
Selling, general and administrative
Total operating expenses
% of revenue167.4%176.3%152.4%134.6%
Loss from operations
% of revenue-67.4%-76.3%-52.4%-34.6%
Other income (expense):
Interest income
Interest expense
Other (expense) income, net
Total other expense, net
Loss before income taxes
Income tax provision
Net loss
% of revenue-200.5%-63.9%-299.9%-75.2%
Diluted net loss per share—
Basic net loss per share—